H.I.G. BioHealth Partners
VC Fund
Miami, United States
H.I.G. BioHealth Partners is a VC fund in Miami focused on Health Care and Biotechnology. H.I.G. BioVentures invests in a broad range of life science companies across multiple sectors and stages of development. Their seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. They invest in companies developing novelproducts for significant unmet medical needs.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 46%
- Fund size:
- $268M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries H.I.G. BioHealth Partners invests in
Stages H.I.G. BioHealth Partners invests in
Countries H.I.G. BioHealth Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 14 (54%)
- Biotechnology 12 (46%)
- Medical 7 (27%)
- Medical Device 7 (27%)
- Therapeutics 5 (19%)
Stage
- Series A 6 (23%)
- Series B 6 (23%)
- Series C 5 (19%)
- Funding Round 4 (15%)
- Series D 2 (8%)
Country
- United States 15 (58%)
- Israel 1 (4%)
- Switzerland 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bruce Robertson
Managing Director
|
Managing Director | Total investments: 7 | Find email | |
Jorge Ramirez
Vice Presidents
|
Vice Presidents | Total investments: 0 | Find email | |
Aaron Davidson
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Michael Wasserman
Managing Director
|
Managing Director | Total investments: 11 | Find email | |
Sami Mnaymneh
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Click Therapeutics
|
Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive datascience platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. | $52M / Series B / Oct 22, 2021 | |
Arvelle Therapeutics
|
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. | $42.7M / Series A / May 27, 2020 | |
Zerigo Health
|
Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | $18M / Series A / Oct 23, 2019 | |
Exagen
|
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based onour proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.Exagen was established in 2002 and is headquartered in Vista, California. | $22.6M / Jul 16, 2019 | |
Intact Vascular
|
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $25M / Series D / May 30, 2019 | |
|
Arvelle Therapeutics
|
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. | $209.8M / Series A / Feb 18, 2019 | |
Iconic Therapeutics
|
Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells toselectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed. | $4.1M / Jun 15, 2018 | |
Neurana Pharmaceuticals
|
Neurana Pharmaceuticals is a biotechnology company that is currently developing a novel treatment for acute muscle spasms. The company was founded in 2013 and headquartered in California, United States. | $60M / Series A / May 08, 2018 | |
|
Intact Vascular
|
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $20M / Series C / Apr 16, 2018 | |
On Target Laboratories
|
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010and is based in Northbrook, Illinois. | $4M / Series B / Mar 14, 2018 | |
| See all 26 investments → | |||
Co-Investors
Longitude Capital
4 deals together
Quaker Partners
4 deals together
Lundbeckfonden Ventures
3 deals together
MPM Capital
3 deals together
New Enterprise Associates
3 deals together
Balance Point Capital Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does H.I.G. BioHealth Partners invest in?
H.I.G. BioHealth Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact H.I.G. BioHealth Partners?
Public channels for H.I.G. BioHealth Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at H.I.G. BioHealth Partners?
The team at H.I.G. BioHealth Partners includes Bruce Robertson (Managing Director), Jorge Ramirez (Vice Presidents) and Aaron Davidson (Managing Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
